New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS
September 08 2020 - 7:30AM
Biogen Inc. (Nasdaq: BIIB) today announced findings from two
large, real-world studies that provide insight into the clinical
and health disparities that exist for people living with multiple
sclerosis (MS). These data, from MS PATHS (Multiple Sclerosis
Partners Advancing Technology and Health Solutions) and the North
American Registry for Care and Research in Multiple Sclerosis
(NARCRMS), will be presented during MSVirtual2020, the eighth joint
meeting of the Americas Committee for Treatment and Research in
Multiple Sclerosis and the European Committee for Treatment and
Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), to be held
virtually September 11-13, 2020.
“As part of our commitment to the MS community, Biogen supports
research to understand the debilitating impact this disease has on
every aspect of an individual’s life,” said Maha Radhakrishnan,
M.D., Chief Medical Officer at Biogen. “Insights from real-world
datasets, such as MS PATHS and NARCRMS, highlight the health
inequities in Black and Hispanic communities and can potentially
inform effective changes in treatment planning. Additionally,
understanding the connection between clinical results and future
employment status is an important step in addressing a critical
concern for people with MS.”
Real-World Evidence Characterizes Health Inequities for
Black and Hispanic People With MS Real-world data from the
NARCRMS registry, a longitudinal database of more than 700 people
living with MS in the U.S. and Canada, show that ethnic and racial
disparities exist related to occupation, income status, MS-related
disability and type of treatment used. Black people with MS were
more likely to be unemployed and earn less annual income compared
to white people, despite comparable educational levels. Researchers
also found twice as many Black people with MS had substantial
MS-related disability compared to white patients. Additionally,
Hispanic and non-Hispanic Black individuals with MS were also less
likely to use a DMT than white non-Hispanic individuals.
Additional data being presented at MSVirtual2020 from MS PATHS,
a collaboration between Biogen and leading MS centers in the U.S.
and Europe to create a standardized, high-quality data repository
from a diverse real-world population, support these findings. The
results show that Hispanic Americans with MS are younger at age of
onset and diagnosis, with higher levels of cognitive and manual
dexterity impairment when compared to their white non-Hispanic
counterparts. The research is designed to help build awareness of
critical issues of health inequity and inform treatment data
gaps.
Standardized Tests Act as Predictor of
Employment Status Amongst People With MSIn a new analysis
from MS PATHS, researchers utilized the Multiple Sclerosis
Performance Test (MSPT) to quantify MS-related disability in MS
patients based on their cognitive and motor performance and then
assessed whether individuals’ scores correlated with their
employment status over time. The results show that individuals with
MS who demonstrated worsening disability based on walking speed,
manual dexterity and cognitive processing speed were more likely to
be unemployed at two years. Future research will inform early risk
factors for these benchmarks that may inform potential employment
preservation strategies.
Cognitive difficulties and fatigue have been associated with
reduced work productivity in people living with MS.1 In a prior
independent study, real-world data showed that less than half of
working age respondents with MS were gainfully employed or
self-employed, with 62 percent reporting the unemployment was due
to their disease.1 To help address this, Biogen is working to
develop new tools to improve the way healthcare providers monitor
for cognitive and other symptoms of MS both in and out of the
clinic. CogEval, a free iPad®-based app that
allows healthcare providers to routinely track and
evaluate symptoms of cognitive dysfunction in people with MS,
is now available in 39 countries and 22 languages. Konectom is
a smartphone based digital platform that enables individuals with
MS to quantitatively self-assess neurological disability and has
potential applications for clinical research and real-world
use.
Data Presentations Featured at
ACTRIMS-ECTRIMS:Note: All poster presentations from
MSVirtual2020 will be made available online at 8 a.m. ET on Friday,
September 11, 2020.
- Socio-demographic and Clinical Characteristics of Patients With
Multiple Sclerosis by Race and Ethnicity (NARCRMS Registry) (Poster
P0494)
- Characterization of US-based Hispanic Americans With Multiple
Sclerosis (Poster P0444)
- Neuroperformance Test Outcomes as Predictors of Employment in a
Large, Heterogeneous Real-World MS Population: Results from MS
PATHS (Poster P0120)
- KonectomTM Smartphone-based Digital Outcome Assessment of
Cognitive and Motor Function in Multiple Sclerosis (Poster
P0102)
About BiogenAt Biogen, our mission is clear: we
are pioneers in neuroscience. Biogen discovers, develops and
delivers worldwide innovative therapies for people living with
serious neurological and neurodegenerative diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners
Walter Gilbert and Phillip Sharp. Today Biogen has the leading
portfolio of medicines to treat multiple sclerosis, has introduced
the first approved treatment for spinal muscular atrophy,
commercializes biosimilars of advanced biologics and is focused on
advancing research programs in multiple sclerosis and
neuroimmunology, Alzheimer’s disease and dementia, neuromuscular
disorders, movement disorders, ophthalmology, immunology,
neurocognitive disorders, acute neurology and pain.
We routinely post information that may be important to investors
on our website at www.biogen.com. To learn more, please visit
www.biogen.com and follow us on social media – Twitter,
LinkedIn, Facebook, YouTube.
Biogen Safe Harbor This news release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, relating to the results of certain real-world
data; the identification and treatment of MS; and our research and
development program for the treatment of MS. These forward-looking
statements may be identified by words such as “aim,” “anticipate,”
“believe,” “could,” “estimate,” “expect,” “forecast,” “goal,”
“intend,” “may,” “plan,” “possible,” “potential,” “will,” “would”
and other words and terms of similar meaning. Drug development and
commercialization involve a high degree of risk, and only a small
number of research and development programs result in
commercialization of a product. Results in early stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these statements
or the scientific data presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation the occurrence of
adverse safety events and/or unexpected concerns that may arise
from additional data or analysis; risks of unexpected costs or
delays; failure to protect and enforce our data, intellectual
property and other proprietary rights and uncertainties relating to
intellectual property claims and challenges; product liability
claims; third party collaboration risks; and the direct and
indirect impacts of the ongoing COVID-19 pandemic on our business,
results of operations and financial condition. The foregoing sets
forth many, but not all, of the factors that could cause actual
results to differ from our expectations in any forward-looking
statement. Investors should consider this cautionary statement, as
well as the risk factors identified in our most recent annual or
quarterly report and in other reports we have filed with the U.S.
Securities and Exchange Commission. These statements are based on
our current beliefs and expectations and speak only as of the date
of this news release. We do not undertake any obligation to
publicly update any forward-looking statements, whether as a result
of new information, future developments or otherwise.
References:1. Kobelt G, Langdon D, Jönsson L. The effect of
self-assessed fatigue and subjective cognitive impairment on work
capacity: The case of multiple sclerosis. Mult Scler.
2019;25(5):740-749.
MEDIA CONTACT:David Caouette+ 1 617 679
4945public.affairs@biogen.com |
INVESTOR CONTACT:Joe Mara+1 781 464 2442IR@biogen.com
|
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024